Empty Iv Bag MarketSize, Share & Industry Analysis, 2026-2034By TypeBy ApplicationBy Chamber TypeBy CapacityBy Distribution Channel
Full title & scope — all 5 axes with their segments
Empty Iv Bag Market Size, Share & Industry Analysis, By Type (PVC Empty IV Bags, Non-PVC Empty IV Bags), By Application (Hospital, Clinic), By Chamber Type (Single Chamber, Multi-chamber), By Capacity (251-1000 mL, Above 1000 mL, Up to 250 mL), By Distribution Channel (Direct/Institutional Tenders, Retail Pharmacy & Distributors), and Regional Forecast, 2026-2034
How the estimates were built: data sources, modelling approach and validation steps.
- 01By TypePVC Empty IV Bags · Non-PVC Empty IV Bags
- 02By ApplicationHospital · Clinic
- 03By Chamber TypeSingle Chamber · Multi-chamber
- 04By Capacity251-1000 mL · Above 1000 mL · Up to 250 mL
- 05By Distribution ChannelDirect/Institutional Tenders · Retail Pharmacy & Distributors
- 06By Region
Market Analysis & Outlook
An empty IV bag is a flexible plastic container, made from PVC or non-PVC polymer film, sold unfilled for later fill-finish with intravenous fluids, injectable medications, or parenteral nutrition solutions. Buyers are pharmaceutical manufacturers, contract fill-finish operators, compounding pharmacies, and hospitals and clinics that prepare or receive sterile fluid products. Bags vary by chamber configuration, fill volume, and film material to suit different clinical delivery and drug-compatibility needs.
USD 2.85 billion of revenue was recorded in the global empty iv bag market in 2025. By 2034 the figure reaches USD 5.37 billion, a compound annual growth rate of 7.37% through the forecast period, along a series that runs USD 2.13 billion in 2020, USD 2.68 billion in 2024, USD 3.04 billion in 2026 and USD 4.03 billion in 2030.
Composition changes more than the total does. Non-PVC Empty IV Bags, at 9.81%, outgrows PVC Empty IV Bags at 5.48%, and its share moves from 38.9% to 48%. PVC Empty IV Bags stays the largest line throughout, at USD 1.74 billion in 2025 and USD 2.79 billion in 2034. Share moves toward Non-PVC Empty IV Bags and away from PVC Empty IV Bags, though no line shrinks in revenue terms.
The application split puts Hospital first, at USD 2.22 billion and 77.9% of revenue in 2025, rising to USD 3.97 billion and 73.9% in 2034. Clinic grows faster at 9.28% against 6.68%, moving from 22.1% of revenue to 26.1% by 2034. It cuts the same total as the type axis from a different commercial angle, so revenue does not add across the two.
The regional order runs from North America at 34% of 2025 revenue down to Middle East and Africa at 5%. North America is worth USD 0.97 billion in 2025 and USD 1.66 billion in 2034; Asia Pacific, second at 28%, moves from USD 0.8 billion to USD 1.72 billion. Share shifts toward Asia Pacific, Latin America and Middle East and Africa over the forecast period, so the regional split repays a close reading.
Coverage extends to five regions, two type lines and five segmentation axes over the full fifteen years. The 2025 total itself is a triangulation of published figures and category proxies, short of a directly sourced total, and the splits below are estimated on that same basis, a bound on their precision worth carrying into any use of them.
Market Size, 2020–2034
USD BillionRevenue in USD Billion. Values up to 2025 are actuals; 2026–2034 are forecast.
Key Takeaways
- A forecast-period rate of 7.37% takes the market from USD 2.85 billion in 2025 to USD 5.37 billion in 2034, against 6% recorded over the 2020-2025 historical period.
- PVC Empty IV Bags is the largest type line at USD 1.74 billion in 2025, a 61.1% share, reaching USD 2.79 billion and 52% of revenue by 2034.
- Non-PVC Empty IV Bags is the fastest-growing line at 9.81%, lifting its share from 38.9% in 2025 to 48% in 2034 and its revenue from USD 1.11 billion to USD 2.58 billion.
- The bull case puts 2034 revenue at USD 6.01 billion and the bear case at USD 4.83 billion, either side of the USD 5.37 billion base case, each with its own stated assumption in the full report.
- The largest region is North America, generating USD 0.97 billion in 2025 (34% of the global total) and USD 1.66 billion by 2034, ahead of Asia Pacific at 28%.
- The United States accounts for 84.5% of North America in the base year, worth USD 0.82 billion in 2025 and reaching USD 1.39 billion by 2034, the worked country example carried through that region's chapters.
- Every line on all five segmentation axes and in each of the five regions carries its own revenue, share and growth rate for all fifteen years, 2020 through 2034, on a 2025 base.
Market Trends
Revenue Share, By by type
Base year 2025PVC Empty IV Bags leads with 61.1% of by type segment revenue.
Share of by type segment revenue, most recent base year.
Three things move over 2026-2034, and they are worth separating: the type mix, the regional balance, and the 7.37% compounding underneath both.
The direction of the market is not in question in any of the three. Each line and each region grows in revenue terms; what separates them is which takes the larger part of the growth.
Non-PVC Empty IV Bags outpaces PVC Empty IV Bags. Non-PVC Empty IV Bags grows at 9.81% across 2026-2034 against 5.48% for PVC Empty IV Bags, the widest spread on the type axis. Non-PVC Empty IV Bags takes its share of revenue from 38.9% to 48% while PVC Empty IV Bags gives up ground, from 61.1% to 52%. Revenue rises on both sides; USD 1.11 billion to USD 2.58 billion and USD 1.74 billion to USD 2.79 billion respectively, so this is a change in composition, not a contraction, and one forecast window is long enough for it to matter.
The regional balance moves. Asia Pacific moves from 28% of revenue in 2025 to 32% in 2034, worth USD 0.8 billion rising to USD 1.72 billion; Latin America moves from 7% of revenue in 2025 to 7.5% in 2034, worth USD 0.2 billion rising to USD 0.4 billion; Middle East and Africa moves from 5% of revenue in 2025 to 5.5% in 2034, worth USD 0.14 billion rising to USD 0.3 billion. Against that, North America at 34% moving to 31%, Europe at 26% moving to 24%, a fall in share, not in revenue. Growth is therefore not something a participant inherits from the market; it depends on which regions its revenue is weighted toward.
Growth compounds at 7.37% without a step change. Reading the series: USD 2.13 billion in 2020, USD 2.68 billion in 2024, USD 2.85 billion in 2025, USD 3.04 billion in 2026, USD 4.03 billion in 2030 and USD 5.37 billion in 2034. No year breaks the trajectory, and the 7.37% forecast rate compares with 6% recorded over 2020-2025, a continuation, not an inflection. A plan built on this market is therefore a plan about capturing a share of steady expansion, which is decided on the type and regional axes, not by the headline rate.
Market Growth Factors
The fastest line decides the blended rate
Market Drivers
3- 01The fastest line decides the blended rate
Non-PVC Empty IV Bags compounds at 9.81% against 7.37% for the market, rising from USD 1.11 billion in 2025 to USD 2.58 billion in 2034 and from 38.9% of revenue to 48%. Because the spread to PVC Empty IV Bags at 5.48% is this wide, the headline 7.37% is a weighted result, not a rate any single line achieves. That makes position on the type axis a growth decision, not a product one.
- 02North America carries 34% of the base and keeps growing
The largest regional base is North America: USD 0.97 billion in 2025 at 34% of the global total, USD 1.66 billion by 2034, still 31%. Behind it, Asia Pacific holds 28%; USD 0.8 billion rising to USD 1.72 billion. Because both the existing revenue and the revenue added concentrate in these two, regional weighting matters more to a forecast than regional count does.
- 03The base has grown every year since 2020
USD 2.13 billion in 2020, USD 2.68 billion in 2024 and USD 2.85 billion in 2025: 6% compound growth before the forecast period even begins. The forecast period then runs at 7.37%, ending 2034 at USD 5.37 billion. A forecast extending an observed trend is a different proposition from one proposing a turn, and that is why no ramp is applied: the 7.37% runs evenly across the period.
Growth drivers
| # | Growth driver | Impact | Gross contribution (Billion) | 2026-28 | 2029-31 | 2032-34 |
|---|---|---|---|---|---|---|
| 1 | Rising volume of inpatient and surgical procedures requiring intravenous fluid delivery | High | +0.85 | High | High | High |
| 2 | Regulatory shift away from PVC and DEHP-based bag materials | Medium-High | +0.55 | Medium | High | High |
| 3 | Expansion of home and outpatient infusion therapy | Medium-High | +0.45 | Medium | Medium | High |
| 4 | Healthcare infrastructure investment across Asia Pacific and Latin America | Medium | +0.4 | Medium | High | High |
| 5 | Adoption of multi-chamber bags for parenteral nutrition and combination therapy | Medium | +0.35 | Medium | Medium | Medium |
| 6 | Others | Low | +0.12 | Low | Low | Low |
| Total | +2.72 | |||||
Restraints
| # | Restraint | Impact | Estimated reduction (Billion) | 2026-28 | 2029-31 | 2032-34 |
|---|---|---|---|---|---|---|
| 1 | Pricing pressure from centralized hospital tenders and group purchasing organizations | Medium | −0.12 | High | Medium | Medium |
| 2 | Volatility in resin and raw material costs | Low | −0.08 | Medium | Medium | Low |
| Total | −0.2 | |||||
Drivers contribute 2.72 Billion and restraints remove 0.2 Billion, a net 2.52 Billion, which is the revenue the market adds between the base year and 2034. Contributions are CDI estimates, apportioned so that they reconcile with the forecast rather than being read from it.
Growth in the global empty iv bag market comes from three measurable sources over 2026-2034: the market's own compounding at 7.37%, the share gained by faster-growing type lines, and expansion in the regions taking a larger part of global revenue.
Restraining Factors
What holds the forecast back
Market Restraints
2- 01What holds the forecast back
Where the forecast could miss: the bear case assumes slower material substitution and tighter hospital capital budgets that delay the transition to non-PVC and multi-chamber bag formats. That path reaches USD 4.83 billion by 2034 instead of USD 5.37 billion, off an unchanged USD 2.85 billion in 2025.
- 02PVC Empty IV Bags grows below the market rate
PVC Empty IV Bags carries 61.1% of 2025 revenue at USD 1.74 billion but compounds at 5.48% against 7.37% for the market, taking its share to 52% by 2034 even as revenue rises to USD 2.79 billion. Because it carries that much of the base, its pace holds the blended rate down more than any faster line lifts it.
Market Opportunities
What the bull case turns on
Market Opportunities
2- 01What the bull case turns on
What would beat the forecast: the bull case assumes faster regulatory-driven substitution toward non-PVC film and a quicker build-out of outpatient and homecare infusion capacity in Asia Pacific and Latin America than the base case expects. That case reaches USD 6.01 billion in 2034 against USD 5.37 billion, and it is worth testing against a reader's own read of the market.
- 02Non-PVC Empty IV Bags is where share changes hands
Non-PVC Empty IV Bags grows at 9.81% against 7.37% for the market, adding revenue from USD 1.11 billion in 2025 to USD 2.58 billion in 2034 and taking its share from 38.9% to 48%. It is the place on this axis where share changes hands at scale, so it is where an entrant can take position without displacing the incumbent in PVC Empty IV Bags.
Market Challenges
The total depends on a single line
Market Challenges
2- 01The total depends on a single line
One line dominates: PVC Empty IV Bags, at 61.1% of revenue in 2025 and 52% in 2034, worth USD 1.74 billion and USD 2.79 billion. A market leaning this heavily on one type line concentrates its exposure there, and a shift in demand for that line moves the total more than any other single change on the axis.
- 02North America is largely the United States
84.5% of the leading region is one country: the United States, at USD 0.82 billion against North America's USD 0.97 billion in 2025, and USD 1.39 billion by 2034. The consequence is that regional risk here is really country risk wearing a larger label.
Segmentation Analysis
5 axesSegmentation runs along five axes: type, application, chamber type, capacity and distribution channel. They are alternative readings of one revenue pool, not parts that sum to it.
All two type lines expand in revenue terms over the forecast period. Share is the dividing line; one takes it, the other cedes it.
By Type · 2 segments
Scale in PVC Empty IV Bags and Growth in Non-PVC Empty IV Bags Define the Type Axis
- Largest PVC Empty IV Bags · 61.1%
- Fastest Non-PVC Empty IV Bags · 9.8%
- Moves most PVC Empty IV Bags · -9.1 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| PVC Empty IV Bags | $1.74B | 61.1% | $2.79B | 52%-9.1 | 5.5% |
| Non-PVC Empty IV Bags | $1.11B | 38.9% | $2.58B | 48%+9.1 | 9.8% |
PVC leads because of legacy manufacturing infrastructure, established hospital procurement relationships, and lower per-unit cost; Non-PVC grows fastest due to regulatory pressure against plasticizer-based materials, clinical preference in neonatal and oncology care, and hospital sustainability procurement mandates favoring safer alternatives. PVC Empty IV Bags remains the largest line through 2034, so the axis changes in proportion, not in order. Every year of the series is priced on this axis, making it the reference cut for the rest of the report.
By Application · 2 segments
Scale in Hospital and Growth in Clinic Define the Application Axis
- Largest Hospital · 77.9%
- Fastest Clinic · 9.3%
- Moves most Hospital · -4 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Hospital | $2.22B | 77.9% | $3.97B | 73.9%-4 | 6.7% |
| Clinic | $0.63B | 22.1% | $1.40B | 26.1%+4 | 9.3% |
Hospital leads because inpatient care remains the dominant setting for intravenous therapy, supported by centralized procurement and continuous fluid management needs; Clinic grows fastest as outpatient infusion, ambulatory surgery, and homecare-linked treatment expand, shifting a portion of routine IV administration outside the hospital setting. By 2034 Hospital is still ahead, making this a shift in weight, not a change of leader.
By Chamber Type · 2 segments
Scale in Single Chamber and Growth in Multi-chamber Define the Chamber type Axis
- Largest Single Chamber · 70.2%
- Fastest Multi-chamber · 9.5%
- Moves most Single Chamber · -6.1 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Single Chamber | $2B | 70.2% | $3.44B | 64.1%-6.1 | 6.2% |
| Multi-chamber | $0.85B | 29.8% | $1.93B | 35.9%+6.1 | 9.5% |
Single Chamber leads because standard saline and dextrose infusions remain the most common clinical use case and require no internal separation; Multi-chamber grows fastest as parenteral nutrition and combination-therapy regimens favor pre-mixed, ready-to-use formats that reduce compounding steps and contamination risk at the bedside. Single Chamber remains the largest line through 2034, so the axis changes in proportion, not in order.
By Capacity · 3 segments
Above 1000 mL Outpaces the Axis While 251-1000 mL Holds the Largest Share
- Largest 251-1000 mL · 57.9%
- Fastest Above 1000 mL · 9.2%
- Moves most Above 1000 mL · +4 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| 251-1000 mL | $1.65B | 57.9% | $2.90B | 54%-3.9 | 6.5% |
| Above 1000 mL | $0.68B | 23.9% | $1.50B | 27.9%+4 | 9.2% |
| Up to 250 mL | $0.52B | 18.2% | $0.97B | 18.1%-0.1 | 7.2% |
The mid-range volume band leads because it matches the fluid replacement and medication delivery needs of most general ward and emergency use; the largest-volume band grows fastest as parenteral nutrition and extended critical-care infusion protocols call for greater single-bag capacity, while the smallest band serves a stable pediatric and specialty niche. By 2034 251-1000 mL is still ahead, making this a shift in weight, not a change of leader.
By Distribution Channel · 2 segments
Retail Pharmacy & Distributors Outpaces the Axis While Direct/Institutional Tenders Holds the Largest Share
- Largest Direct/Institutional Tenders · 82.1%
- Fastest Retail Pharmacy & Distributors · 9.8%
- Moves most Direct/Institutional Tenders · -4.1 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Direct/Institutional Tenders | $2.34B | 82.1% | $4.19B | 78%-4.1 | 6.7% |
| Retail Pharmacy & Distributors | $0.51B | 17.9% | $1.18B | 22%+4.1 | 9.8% |
Direct and institutional tenders lead because hospital systems and group purchasing organizations negotiate multi-year supply contracts directly with manufacturers to secure consistent volumes; retail and distributor channels grow fastest as homecare infusion and smaller clinic networks that lack tender leverage increasingly source through intermediaries. By 2034 Direct/Institutional Tenders is still ahead, making this a shift in weight, not a change of leader.
Regional Insights
Regional Revenue Share
Base year 2025Share of global revenue in the base year.
Only the leading region's share is published outside the report; pins mark the region, not a specific country.
North America Market Analysis
The largest region covered — 3.1 points of share move elsewhere by 2034, while revenue still grows 1.7×.
- Rank 1 of 5
- 2025 share 34%
- By 2034 30.9%
- Revenue $0.97B → $1.66B
USD 0.97 billion of 2025 revenue is generated in North America, 34% of the global empty iv bag market rising to USD 1.66 billion in 2034. It is a leading region on this axis, first by revenue throughout the period.
31% of global revenue sits here in 2034, below the 2025 level, while nothing contracts here; other regions simply grow faster, which shows up as relative weight, not as falling revenue.
The type mix reported at global level applies here, with PVC Empty IV Bags the largest line at 61.1% of 2025 revenue and Non-PVC Empty IV Bags the fastest-growing at 9.81%. North America is reported axis by axis and country by country in the full study.
United States
Sets the pace for North America at 84.5% of it, growing 1.7×.
- In region 1 of 2
- Of region 84.5%
- Of global 28.8%
- Revenue $0.82B → $1.39B
The largest single market in North America is the United States, at USD 0.82 billion in 2025 and USD 1.39 billion in 2034. Because it is 84.5% of the region in the base year, North America's totals move with this one country instead of a spread of them. Set against USD 0.97 billion and USD 1.66 billion for the region, it is why this market, and not a smaller one, is the one reported in full.
the United States buys along the same lines as the market globally; PVC Empty IV Bags first at 61.1% of 2025 revenue and 52% in 2034, Non-PVC Empty IV Bags fastest at 9.81% on a share moving from 38.9% to 48%. Since 84.5% of North America's revenue is generated here, the regional numbers inherit this market's mix instead of smoothing it out. Per-type revenue for the United States appears on its own in the full report.
The Food and Drug Administration regulates empty intravenous bags as medical devices under its device classification framework, since the container is intended to hold and deliver a sterile fluid to a patient. A manufacturer must clear the product through the appropriate premarket pathway before marketing it, typically by demonstrating equivalence to a legally marketed predicate container. Facilities producing these bags must operate under the Quality System Regulation, covering design controls, sterilization validation, and material biocompatibility testing. Labeling must identify the manufacturer, lot, sterility status, and intended use, and materials are commonly tested against compendial standards set by the United States Pharmacopeia for container closure integrity and leachable substances.
The suppliers tracked in this study (Sippex IV Bag (U.S), Technoflex (Japan), Wipak Group (Germany), Baxter (U.S), B. Braun (Germany), ICU Medical, Inc. (U.S), POLYCINE GmbH (Germany), RENOLIT SE (Germany), Pfizer Inc. (U.S), West Pharmaceutical Services Inc. (U.S), Jinan Youlyy Industrial Co., Ltd. (China) and Jiangsu Eyoung Medical Devices Co. Ltd. (China) and others) compete in the United States across the type lines above. The commercially relevant division is 61.1% of 2025 revenue in PVC Empty IV Bags, where the volume is, against 9.81% growth in Non-PVC Empty IV Bags, where share moves. Country-level positioning and shares for each of these companies are part of the full report, not of this summary.
Canada
2nd-largest in North America, growing 1.8×.
- In region 2 of 2
- Of region 15.5%
- Of global 5.3%
- Revenue $0.15B → $0.27B
Canada is sized at USD 0.15 billion in 2025, rising to USD 0.27 billion by 2034; 5.3% of global revenue and 15.5% of North America. It is reported separately from the United States across every segmentation axis in the full report.
Europe Market Analysis
The 3rd-largest region covered — 2 points of share move elsewhere by 2034, while revenue still grows 1.7×.
- Rank 3 of 5
- 2025 share 26%
- By 2034 24%
- Revenue $0.74B → $1.29B
26% of the global empty iv bag market sits in Europe in 2025, worth USD 0.74 billion and reaches USD 1.29 billion by 2034. It is a leading region on this axis, third by revenue throughout the period.
By 2034 the share stands at 24%, while nothing contracts here; other regions simply grow faster, which shows up as relative weight, not as falling revenue.
The type mix reported at global level applies here, with PVC Empty IV Bags the largest line at 61.1% of 2025 revenue and Non-PVC Empty IV Bags the fastest-growing at 9.81%. Europe is reported axis by axis and country by country in the full study.
Germany
The largest market in Europe, growing 1.7×.
- In region 1 of 3
- Of region 29.7%
- Of global 7.7%
- Revenue $0.22B → $0.37B
29.7% of Europe's base-year revenue comes from Germany; USD 0.22 billion, rising to USD 0.37 billion by 2034. It accounts for 29.7% of regional revenue in the base year, the largest single share without dominating the region outright. The region itself runs USD 0.74 billion to USD 1.29 billion over the same period, and this is the market carrying the country-level detail in the full report.
The type pattern in Germany is the global one: 61.1% of 2025 revenue in PVC Empty IV Bags, 52% by 2034, against 9.81% growth in Non-PVC Empty IV Bags taking it from 38.9% to 48%. Its 29.7% weight in Europe means those movements carry straight into the regional totals. The full report reports Germany by type separately.
Empty intravenous bags sold in Germany fall under the European Union's Medical Device Regulation, administered domestically through the national competent authority alongside notified bodies that assess conformity before a product carries the CE mark. As a sterile fluid-path container, the bag is classified according to the duration and route of patient contact, and the manufacturer must compile technical documentation covering material safety, sterilization method, and clinical evaluation. A quality management system certified to the relevant ISO standard for medical device manufacturing is expected, and labelling must meet the regulation's requirements for language, traceability through a unique device identifier, and instructions for safe use. Post-market surveillance obligations continue after the product reaches the market.
In Germany the field is Sippex IV Bag (U.S), Technoflex (Japan), Wipak Group (Germany), Baxter (U.S), B. Braun (Germany), ICU Medical, Inc. (U.S), POLYCINE GmbH (Germany), RENOLIT SE (Germany), Pfizer Inc. (U.S), West Pharmaceutical Services Inc. (U.S), Jinan Youlyy Industrial Co., Ltd. (China) and Jiangsu Eyoung Medical Devices Co. Ltd. (China) and others. Volume sits in PVC Empty IV Bags at 61.1% of 2025 revenue; movement sits in Non-PVC Empty IV Bags at 9.81% growth.
United Kingdom
2nd-largest in Europe, growing 1.7×.
- In region 2 of 3
- Of region 21.6%
- Of global 5.6%
- Revenue $0.16B → $0.27B
The United Kingdom is sized at USD 0.16 billion in 2025, rising to USD 0.27 billion by 2034; 5.6% of global revenue and 21.6% of Europe. It is reported separately from Germany across every segmentation axis in the full report.
France
3rd-largest in Europe, growing 1.7×.
- In region 3 of 3
- Of region 17.6%
- Of global 4.6%
- Revenue $0.13B → $0.22B
France is sized at USD 0.13 billion in 2025, rising to USD 0.22 billion by 2034; 4.6% of global revenue and 17.6% of Europe. It is reported separately from Germany across every segmentation axis in the full report.
Asia Pacific Market Analysis
The 2nd-largest region covered, and the one gaining the most — it picks up 4 points of share by 2034, while revenue still grows 2.1×.
- Rank 2 of 5
- 2025 share 28%
- By 2034 32%
- Revenue $0.80B → $1.72B
28% of the global empty iv bag market sits in Asia Pacific in 2025, worth USD 0.8 billion with USD 1.72 billion projected for 2034. By revenue it sits second across the study, and the ranking does not change between 2025 and 2034.
Share climbs to 32% by 2034, on growth above the market's own 7.37%, and with a bigger contribution to the revenue added over the period than the base-year figure suggests.
Within the region the type split tracks the global one; 61.1% of 2025 revenue in PVC Empty IV Bags, fastest growth of 9.81% in Non-PVC Empty IV Bags. The full report breaks Asia Pacific out along every axis and by country.
China
The largest market in Asia Pacific, growing 2.2×.
- In region 1 of 3
- Of region 40%
- Of global 11.2%
- Revenue $0.32B → $0.71B
The largest single market in Asia Pacific is China, at USD 0.32 billion in 2025 and USD 0.71 billion in 2034. It accounts for 40% of regional revenue in the base year, the largest single share without dominating the region outright. The region itself runs USD 0.8 billion to USD 1.72 billion over the same period, and this is the market carrying the country-level detail in the full report.
Composition here matches the global split: the largest line is PVC Empty IV Bags at 61.1% of 2025 revenue, easing to 52% by 2034, and the fastest is Non-PVC Empty IV Bags at 9.81%, from 38.9% to 48%. Its 40% weight in Asia Pacific means those movements carry straight into the regional totals. Per-type revenue for China appears on its own in the full report.
In China, empty intravenous bags are regulated as medical devices by the National Medical Products Administration, which assigns products to a risk-based classification before any registration application can proceed. A domestic or foreign manufacturer must obtain a medical device registration certificate, supported by testing reports on material composition, sterility, and container integrity conducted at recognized laboratories, along with a quality management system audit. Labelling and Chinese-language instructions must disclose the manufacturer, intended use, and storage conditions, and imported products additionally require a local agent responsible for post-market obligations. Standards conformity is generally assessed against national pharmacopoeia and medical device standards rather than accepting foreign certification alone.
In China the field is Sippex IV Bag (U.S), Technoflex (Japan), Wipak Group (Germany), Baxter (U.S), B. Braun (Germany), ICU Medical, Inc. (U.S), POLYCINE GmbH (Germany), RENOLIT SE (Germany), Pfizer Inc. (U.S), West Pharmaceutical Services Inc. (U.S), Jinan Youlyy Industrial Co., Ltd. (China) and Jiangsu Eyoung Medical Devices Co. Ltd. (China) and others. The commercially relevant division is 61.1% of 2025 revenue in PVC Empty IV Bags, where the volume is, against 9.81% growth in Non-PVC Empty IV Bags, where share moves.
India
2nd-largest in Asia Pacific, growing 2.2×.
- In region 2 of 3
- Of region 22.5%
- Of global 6.3%
- Revenue $0.18B → $0.40B
6.3% of global revenue is generated in India; USD 0.18 billion in 2025, reaching USD 0.4 billion in 2034, and 22.5% of Asia Pacific.
Japan
3rd-largest in Asia Pacific, growing 2.0×.
- In region 3 of 3
- Of region 17.5%
- Of global 4.9%
- Revenue $0.14B → $0.28B
Japan is sized at USD 0.14 billion in 2025, rising to USD 0.28 billion by 2034; 4.9% of global revenue and 17.5% of Asia Pacific. It is reported separately from China across every segmentation axis in the full report.
Latin America Market Analysis
The 4th-largest region covered — it picks up 0.4 points of share by 2034, while revenue still grows 2.0×.
- Rank 4 of 5
- 2025 share 7%
- By 2034 7.4%
- Revenue $0.20B → $0.40B
Latin America holds 7% of the global empty iv bag market in 2025, worth USD 0.2 billion with USD 0.4 billion projected for 2034. By revenue it sits fourth across the study, and the ranking does not change between 2025 and 2034.
By 2034 the share has moved up to 7.5%, on growth above the market's own 7.37%, and with a bigger contribution to the revenue added over the period than the base-year figure suggests.
PVC Empty IV Bags leads here as it does globally, at 61.1% of 2025 revenue, and Non-PVC Empty IV Bags again grows fastest at 9.81%. Per-axis and per-country detail for Latin America sits in the full report.
Brazil
The largest market in Latin America, growing 2.0×.
- In region 1 of 2
- Of region 55%
- Of global 3.9%
- Revenue $0.11B → $0.22B
55% of Latin America's base-year revenue comes from Brazil; USD 0.11 billion, rising to USD 0.22 billion by 2034. At 55% of the region in 2025 it leads, but a majority of Latin America's revenue is generated in other markets. The region itself runs USD 0.2 billion to USD 0.4 billion over the same period, and this is the market carrying the country-level detail in the full report.
Brazil buys along the same lines as the market globally; PVC Empty IV Bags first at 61.1% of 2025 revenue and 52% in 2034, Non-PVC Empty IV Bags fastest at 9.81% on a share moving from 38.9% to 48%. Because the country carries 55% of Latin America, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. Brazil carries its own type breakdown in the full report.
Brazil's health regulatory authority, Anvisa, oversees empty intravenous bags as medical devices, placing them within its risk classification system that determines whether a product may be registered through a simplified notification or requires a fuller technical review. Manufacturers must demonstrate compliance with Brazilian good manufacturing practice requirements, which Anvisa verifies either directly or by recognizing certification from other regulatory systems under its reliance pathways. Sterility, material biocompatibility, and container integrity testing must be documented in the registration dossier, and Portuguese-language labelling must state the manufacturer, batch identification, expiry, and storage instructions. A local registration holder based in Brazil is required for any manufacturer without a domestic presence.
In Brazil the field is Sippex IV Bag (U.S), Technoflex (Japan), Wipak Group (Germany), Baxter (U.S), B. Braun (Germany), ICU Medical, Inc. (U.S), POLYCINE GmbH (Germany), RENOLIT SE (Germany), Pfizer Inc. (U.S), West Pharmaceutical Services Inc. (U.S), Jinan Youlyy Industrial Co., Ltd. (China) and Jiangsu Eyoung Medical Devices Co. Ltd. (China) and others. PVC Empty IV Bags, at 61.1% of 2025 revenue, is where the volume sits, and Non-PVC Empty IV Bags, growing at 9.81%, is where position changes hands over the forecast period.
Mexico
2nd-largest in Latin America, growing 2.0×.
- In region 2 of 2
- Of region 30%
- Of global 2.1%
- Revenue $0.06B → $0.12B
2.1% of global revenue is generated in Mexico; USD 0.06 billion in 2025, reaching USD 0.12 billion in 2034, and 30% of Latin America.
Middle East and Africa Market Analysis
The 5th-largest region covered — it picks up 0.6 points of share by 2034, while revenue still grows 2.1×.
- Rank 5 of 5
- 2025 share 5%
- By 2034 5.6%
- Revenue $0.14B → $0.30B
USD 0.14 billion of 2025 revenue is generated in Middle East and Africa, 5% of the global empty iv bag market rising to USD 0.3 billion in 2034. It is a marginal region on this axis, fifth by revenue throughout the period.
By 2034 the share has moved up to 5.5%, so the region grows faster than the market's 7.37% and takes a larger part of the revenue added by 2034 than its 2025 weight implies.
PVC Empty IV Bags leads here as it does globally, at 61.1% of 2025 revenue, and Non-PVC Empty IV Bags again grows fastest at 9.81%. Revenue for Middle East and Africa is broken out by every segmentation axis and by country in the full report.
Saudi Arabia
The largest market in Middle East and Africa, growing 2.2×.
- In region 1 of 2
- Of region 35.7%
- Of global 1.8%
- Revenue $0.05B → $0.11B
35.7% of Middle East and Africa's base-year revenue comes from Saudi Arabia; USD 0.05 billion, rising to USD 0.11 billion by 2034. At 35.7% of the region in 2025 it leads, but a majority of Middle East and Africa's revenue is generated in other markets. Against regional totals of USD 0.14 billion in 2025 and USD 0.3 billion in 2034, it is the country the full report breaks out in detail.
Demand in Saudi Arabia follows the type mix reported at global level: PVC Empty IV Bags is the largest line at 61.1% of 2025 revenue, moving to 52% by 2034, while Non-PVC Empty IV Bags grows fastest at 9.81% and takes its share from 38.9% to 48%. With 35.7% of Middle East and Africa concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. Saudi Arabia carries its own type breakdown in the full report.
In Saudi Arabia, the Saudi Food and Drug Authority regulates empty intravenous bags under its medical device framework, which follows the classification and conformity assessment principles set out by the International Medical Device Regulators Forum. A manufacturer must register the product through the authority's electronic system and hold a valid marketing authorization before distribution, generally supported by evidence of conformity already granted by a reference regulatory body such as the United States, the European Union, or another recognized jurisdiction. Labelling must appear in Arabic alongside English, identifying the manufacturer, authorized local representative, sterility status, and intended use. Ongoing compliance includes adverse event reporting and maintenance of authorization through periodic renewal.
In Saudi Arabia the field is Sippex IV Bag (U.S), Technoflex (Japan), Wipak Group (Germany), Baxter (U.S), B. Braun (Germany), ICU Medical, Inc. (U.S), POLYCINE GmbH (Germany), RENOLIT SE (Germany), Pfizer Inc. (U.S), West Pharmaceutical Services Inc. (U.S), Jinan Youlyy Industrial Co., Ltd. (China) and Jiangsu Eyoung Medical Devices Co. Ltd. (China) and others. PVC Empty IV Bags, at 61.1% of 2025 revenue, is where the volume sits, and Non-PVC Empty IV Bags, growing at 9.81%, is where position changes hands over the forecast period.
South Africa
2nd-largest in Middle East and Africa, growing 2.0×.
- In region 2 of 2
- Of region 28.6%
- Of global 1.4%
- Revenue $0.04B → $0.08B
Within Middle East and Africa, South Africa accounts for 28.6% of regional revenue and 1.4% of the global total, worth USD 0.04 billion in 2025 and USD 0.08 billion by 2034.
Request this sample to see the full data tables and segment-level detail behind this analysis.
Report Coverage
This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by type, application, chamber type, capacity, distribution channel, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.
Competitive Landscape
Scale in PVC Empty IV Bags and Growth in Non-PVC Empty IV Bags Set the Terms of Competition
The field covered here is Sippex IV Bag (U.S), Technoflex (Japan), Wipak Group (Germany), Baxter (U.S), B. Braun (Germany), ICU Medical, Inc. (U.S), POLYCINE GmbH (Germany), RENOLIT SE (Germany), Pfizer Inc. (U.S), West Pharmaceutical Services Inc. (U.S), Jinan Youlyy Industrial Co., Ltd. (China) and Jiangsu Eyoung Medical Devices Co. Ltd. (China) and others.
The competitive line that matters is the type one, not the geographic one. The largest block of revenue is PVC Empty IV Bags: USD 1.74 billion in 2025 at 61.1% of the total, 52% in 2034. Incumbency there is expensive to challenge. Share moves in Non-PVC Empty IV Bags, growing 9.81% against 5.48% for PVC Empty IV Bags. Holding the first and taking the second are separate capabilities, which is why a market of USD 2.85 billion supports as many suppliers as it does.
Scale in polymer film extrusion and sterile bag assembly separates the largest suppliers, since consistent multi-site capacity is what wins multi-year hospital tender contracts. Regulatory and drug-contact packaging approval experience matters as much as capacity, because non-PVC film substitution requires new material qualifications with each health authority. The largest suppliers combine that approval history with direct hospital distribution relationships built over decades and broad geographic manufacturing footprints. Smaller and regional manufacturers, concentrated in Asia, compete on price and faster lead times for standard single-chamber PVC bags, and on proximity to domestic hospital tenders instead of global reach.
The regional picture sets the entry cost: 34% of revenue is in North America and 28% in Asia Pacific, so a credible global position requires both, while Middle East and Africa at 5% can be served opportunistically.
Profiles, financials, shares and development histories for each company sit in the full report; this summary carries the structure only.
List of Key Empty Iv Bag Market Companies Profiled
12 companies profiled. Company profiles, including financials, product portfolios and recent developments, are part of the full report.
- Sippex IV Bag (U.S)
- Technoflex (Japan)
- Wipak Group (Germany)
- Baxter (U.S)
- B. Braun (Germany)
- ICU Medical, Inc. (U.S)
- POLYCINE GmbH (Germany)
- RENOLIT SE (Germany)
- Pfizer Inc. (U.S)
- West Pharmaceutical Services Inc. (U.S)
- Jinan Youlyy Industrial Co., Ltd. (China)
- Jiangsu Eyoung Medical Devices Co. Ltd. (China) and others
Geographic Coverage
Every market below is broken out separately in the report.
North America
3Europe
8Asia Pacific
12Latin America
3Middle East and Africa
4Key Insights
Report Scope
Study parameters & segmentationThis study covers market size and forecasts over the 2020–2034 period, segmentation across 5 axes (Type, Application, Chamber Type, Capacity, Distribution Channel), regional analysis for 5 regions and their constituent countries, a competitive landscape profiling 12 key companies, and the research methodology behind every estimate.
Segmentation
5 axes + regionFull chapter-and-section structure of the report. Segment, region, and company breakdowns are listed as scope. The underlying figures are in the sample and full report.
Table of Contents+−
Chapter 1.Executive Summary
Chapter 2.Premium Insights
Chapter 3.Market Definition
Chapter 4.Research Methodology
Chapter 5.Strategic Imperatives & Market Outlook
Chapter 6.Go-to-Market (GTM) Strategies
Chapter 7.Market Trends, Strategy & Dynamics
Chapter 8.Porter's Five Forces
Chapter 9.PESTEL Analysis
Chapter 10.Value Chain Analysis
Chapter 11.Supply Chain Analysis
Chapter 12.Macro-Economic Factors
Chapter 13.Market Cost Analysis
Chapter 14.Market Supply-Side Analysis
Chapter 15.Global Empty Iv Bag Market Size & Projections, 2020–2034, Revenue (USD Billion)
Chapter 16.Global Empty Iv Bag Market Overview, By Type, 2020–2034, Revenue (USD Billion)
Chapter 17.Global Empty Iv Bag Market Overview, By Application, 2020–2034, Revenue (USD Billion)
Chapter 18.Global Empty Iv Bag Market Overview, By Chamber Type, 2020–2034, Revenue (USD Billion)
Chapter 19.Global Empty Iv Bag Market Overview, By Capacity, 2020–2034, Revenue (USD Billion)
Chapter 20.Global Empty Iv Bag Market Overview, By Distribution Channel, 2020–2034, Revenue (USD Billion)
Chapter 21.Global Empty Iv Bag Market Size — Segment Comparison
Chapter 22.Global Empty Iv Bag Geography Overview, 2020–2034, Revenue (USD Billion)
Chapter 23.North America Empty Iv Bag Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 24.Europe Empty Iv Bag Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 25.Asia Pacific Empty Iv Bag Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 26.Latin America Empty Iv Bag Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 27.Middle East and Africa Empty Iv Bag Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 28.Application / Use-Case Analysis
Chapter 29.Vendor Capability Scorecard
Chapter 30.Scenario Forecasts
Chapter 31.Top 10 Key Clients of Top 10 Players
Chapter 32.Top 10 Suppliers
Chapter 33.Competitive Landscape
Chapter 34.Partnerships & M&A
Chapter 35.Key Vendor Analysis
Chapter 36.Marketing Strategy Analysis, Distributors & Traders
Chapter 37.Outlook of the Market
Chapter 38.Concluding Analyst Note
List of Figures+−
Structural index generated from this report's own section headings, not verified against the delivered report's actual figure numbering.
List of Tables+−
Structural index generated from this report's own section headings, not verified against the delivered report's actual table numbering.
Segmentation Analysis
5 axesBy Type
2- 01PVC Empty IV Bags
- 02Non-PVC Empty IV Bags
By Application
2- 01Hospital
- 02Clinic
By Chamber Type
2- 01Single Chamber
- 02Multi-chamber
By Capacity
3- 01251-1000 mL
- 02Above 1000 mL
- 03Up to 250 mL
By Distribution Channel
2- 01Direct/Institutional Tenders
- 02Retail Pharmacy & Distributors
Segment categories shown for scope reference. See the Summary tab for revenue share by By Type. Full segment-by-segment detail across every axis is available in the sample and full report.
Research approach
A market size is a claim about the world, and a claim is only as good as the route to it. Every study is built upward from units and prices — what is actually produced, sold or performed, at what it actually changes hands for — rather than from a headline figure divided downwards. Disclosed company revenue is then used to check that build, not to produce it.
The size is built upward from estimated bag unit volumes shipped to hospitals, clinics, and contract fill-finish manufacturers, combined with average realized prices by material type and capacity band, then checked against the disclosed packaging and parenteral-nutrition segment revenue of manufacturers active in flexible IV containers. Where a company's reported segment revenue implies a different average selling price or shipment volume than the bottom-up build, the underlying unit or price assumption is revisited and corrected instead of blending the two figures together. Inputs include estimated annual hospital and compounding-pharmacy fluid throughput, resin and film cost trends that influence pricing, and the shift in unit mix between PVC and non-PVC film across major markets.
The four stages
The same sequence runs behind every published study, whatever the industry. The order matters as much as the steps: the segment axes are fixed before any number is collected, so the model is never reshaped to fit whatever data happens to turn up.
What the build rests on, and what checks it
The two are not interchangeable. The left column produces the number; the right column tests it. When the check disagrees with the build, the answer is to find which bottom-up assumption is wrong — a unit count, a price, a take-up rate — not to split the difference between them.
- Volume actually transacted — units produced, installed, dispensed or procedures performed, counted at the level each is genuinely recorded
- Realised pricing by tier and channel, rather than one blended average applied across the whole market
- Take-up and frequency: how much of the addressable base buys, and how often it repeats
- Disclosed revenue of the companies serving the market, where filings separate it far enough to be usable
- Buyer-side spending totals — capital budgets, procurement lines, or the output of the end market the product is bought against
- Trade and customs flows, where the product crosses borders in a separately recorded form
Data sources
Published data establishes what happened. Only the people transacting in a market can say why, and what is about to change — so the two are collected separately and weighted differently.
- Commercial and product leadership at the companies that supply the market
- Procurement and specification leads at the organisations that buy it
- Distributors, integrators and channel partners, where the market is served indirectly
- Regulatory and standards specialists, where approval governs what can be sold at all
- Company filings, annual reports and investor disclosure
- Government statistics, customs records and regulatory registers
- Trade association output and standards-body publications
- Technical and peer-reviewed literature, where the market rests on a clinical or engineering claim
Interviews target procurement and supply chain managers at hospital systems and group purchasing organizations, production and packaging engineering staff at pharmaceutical and contract fill-finish manufacturers, regulatory affairs personnel handling drug-contact packaging approvals, and commercial leaders at flexible film and bag converters. Sampling weights toward North America and Europe, where centralized hospital procurement and tender data are most transparent, with additional outreach into China, India, and Japan to capture the pace of non-PVC adoption and local manufacturing capacity, and into the Gulf states where public hospital tenders are the primary purchasing route.
Desk research draws on national health expenditure and hospital utilization statistics, medical device registration and clearance records for drug-contact packaging, customs trade codes covering flexible plastic medical containers, and public tender and procurement award notices published by national and regional hospital purchasing bodies. Company-level packaging and parenteral nutrition segment disclosures, resin and film price indices from plastics trade associations, and non-PVC material substitution guidance issued by hospital sustainability and regulatory bodies in the European Union and United States round out the source base.
Desk research runs across proprietary research databases including Factiva, OneSource and Hoovers alongside the public sources above. Modelling and statistical validation are run in SAS and SPSS.
Forecasting
The forecast is not a growth rate applied to a base year. It is built from the drivers that are expected to change, each one stated so a reader can disagree with it.
The forecast is built from projected inpatient and outpatient procedure volumes, the pace at which non-PVC film replaces PVC under regulatory and hospital sustainability pressure, and the rate at which multi-chamber and parenteral nutrition formats displace single-chamber use in higher-acuity care. Pricing is held flat in real terms, since bag pricing is set mainly by tender cycles, not by demand growth. The forecast normalizes for the pandemic-period fluid demand spike already reflected in the historical base, treating post-pandemic volumes as the trend line instead of a rebound. For the forecast to hold, non-PVC substitution and outpatient infusion growth need to continue at their currently observed pace.
Triangulation and validation
No figure enters a report on the strength of one source. Where the two sizing routes disagree the difference is not averaged away — the assumption causing it is isolated, tested against a third independent measure, and either corrected or carried forward as a stated limitation. Historical years are back-tested against the growth actually recorded before any forecast is allowed to run forward from them.
Outputs are checked against recorded historical growth in hospital fluid therapy and parenteral nutrition volumes, so that no forecast segment implies a pace of change outside what the historical base already shows is plausible. Segment share shifts, particularly the move from PVC to non-PVC and from single-chamber to multi-chamber formats, were reviewed against the substitution pace observed in adjacent drug-contact packaging categories facing similar regulatory pressure. Sensitivities were tested on the pace of non-PVC adoption and on hospital procurement budget growth, since these two assumptions carry the most influence over the shape of the forecast curve.
Confidence and limitations
Where an estimate is firm and where it is not is stated rather than left to be inferred from the precision of the number.
Confidence is firmer in the hospital and single-chamber segments, where procurement volumes and material substitution trends are well documented across multiple regulatory and trade sources. It is weaker in the clinic and home-infusion channel and in the smallest Middle Eastern and African markets, where reporting is thin and bag purchasing is often bundled into broader hospital supply contracts instead of tracked separately. A shift in regulatory timing on plasticizer restrictions, or a slower build-out of outpatient infusion capacity than expected, would be the most likely forces to require a revision of this forecast.
Every report purchase includes direct access to the lead analyst for scoping questions on the data, at no extra cost and with no separate booking process.
Request a tailored breakdown by geography, segment, or competitor set beyond what's in the standard report.
Questions This Report Answers
6 questionsWhat is the market size and growth rate, globally and by region?
How is the market segmented, and which segments lead?
Which regions and countries are covered, and how do they compare?
What are the key drivers, restraints, opportunities and challenges?
Who are the leading companies operating in this market?
What trends are expected to shape the market through the forecast period?
Frequently Asked Questions
01What is the Empty Iv Bag Market projected to reach?
USD 5.37 Billion by 2034, CAGR 7.37%
02What years does this report cover?
Study period 2020–2034, base year 2025, historical data 2020-2024, forecast period 2026-2034.
03Which regions are covered?
North America, Europe, Asia Pacific, Latin America, Middle East and Africa.
04Which region accounted for the largest market share?
North America leads with 34% of global revenue through 2034.
05Which segment leads the market?
PVC Empty IV Bags is the largest line by type, at 61.1% of revenue in 2025.
06Who are the key companies profiled?
Sippex IV Bag (U.S), Technoflex (Japan), Wipak Group (Germany), Baxter (U.S), B. Braun (Germany), ICU Medical, Inc. (U.S), POLYCINE GmbH (Germany), RENOLIT SE (Germany), Pfizer Inc. (U.S), West Pharmaceutical Services Inc. (U.S), Jinan Youlyy Industrial Co., Ltd. (China), Jiangsu Eyoung Medical Devices Co. Ltd. (China) and others. Full profiles are part of the paid report.
07Can the segmentation be customized?
Yes. Custom data cuts by geography, segment, or competitor set are available on request.
Why choose CDI
Need this report shaped around your question?
The scope isn't fixed. Tell us what your team needs that the standard edition doesn't cover, and an analyst will come back on what can be adjusted and how long it takes, before you commit to anything.
Most licences include 30–60 hours of customization at no extra cost. See what each licence includes
Additional Companies
Add competitors, suppliers or the peer set you benchmark against to the companies already covered.
Deeper Competitive View
Sharpen the landscape work around your own position: product line, channel, or a named shortlist of rivals.
Extra Segment Splits
Break the market down along an axis the standard scope doesn't cut it by, or go a level deeper inside one.
Application Focus
Narrow the analysis to the specific use cases and end users your team actually sells into.
Different Time Frame
Move the base year, or widen the historical and forecast windows the study is built on.
Country-Level Detail
Go below region level into the individual countries that matter to you, rather than the standard geography split.